PATIENT BENEFITS

After three years of research and development, Hexacath presents its ultimate generation of coronary Bio Active Stent

TITAN2 BAS (Bio Active Stent) combines the benefits of its proprietary Titanox coating (Titanium-Nitride-Oxide) - associated with NO-particles on the stent surface which has proven efficacy to reduce significantly the Major Adverse Cardiac Events (MACE) versus the Bare Metal stents - with the exclusive biomechanical features (ultra low profile and excellent flexibility) of its Helicoidal designed stent platform thus enabling the interventional cardiologist to perform a PTCA procedure in a reduced time minimizing the patient exposure to X-Rays.


STENT BIOCOMPATIBILITY

The mechanism of action of this active coating includes the inhibition of platelet aggregation and fibrinogen binding combined with a minimized inflammatory response due to the complete prevention of toxic ions release reducing consequently the restenosis rate.
Titanium-Nitride-Oxide superior hemocompatibility further reduces acute or sub-acute thrombosis versus conventional stents made in stainless steel or cobalt-chromium, and on the opposite of Drug-Eluting-Stent, does not impede the stent re-endothelialization process thus eliminating the risk of late stent thrombosis.
The stent re-endothelialization is fundamental and critical for the patient safety. Current Drug-Eluting-Stents using cytotoxic or cytostatic tend to prevent the normal cells' growth inside the stent (re-endothelialization) necessary to avoid thrombosis and therefore require long term dual antiplatelet treatments from 6 months up to a lifetime (Recent scientific studies have shown that Titanium-Nitride-Oxide promotes the stent re-endothelialization post implantation versus Bare Metal Stent.
On the contrary, patients treated with TITAN2 do not need a long term dual antiplatelet treatment (1 month only) reducing therefore the risk of bleeding.
TITAN2 impressive series of clinical results show that an Active Coating (Titanium-Nitride-Oxide) can be as effective as a Drug-Eluting-Stent (DES) in terms of clinical restenosis with much less risk of delayed thrombosis.


BIBLIOGRAPHY

  • "If an extra-cardiac procedure is envisaged during the angioplasty, it would be preferable to not use a drug eluting stent."
    Source: "Thrombose de stents actifs ŕ la rapamycine"
    Archives des maladies du coeur et des vaisseaux, tome 97, n°2, february 2004
    >> Download STENT ARTICLE (.pdf file, 200Kb)
  • "There is a likely spectrum of allergic responses to Drug-Eluting-Stent In sensitive patients, varying from benign recations to excessive inflammation with medial destruction, stent malapposition, and aneurysm formation with late in-stent thrombosis."
    "Will the patient be compliant with prolonged antiplatelet therapy ? If not, a BMS (a non-DES) might be preferable."
    Source: "Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy"
    The Lancet 2004; 364: 1519-22
    >> Download STENT ARTICLE (.pdf file, 1315Kb)
  • "Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent. Should We Be Cautious?"
    Source: "Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent. Should We Be Cautious?
    DOI: 10.1161 / 01.CIR.0000116202.41966.D4
    >> Download STENT ARTICLE (.pdf file, 2017Kb)
  • "Most stents are made from 316L Stainless Steel which contain strongly sensitising metals, including Nickel (12%), Chromium (17%) and Molybdenum (2%). Nickel, Chromium and Molybdenum ions are eluted from stents. The action of blood, saline, proteins and mechanical stress increases the release of these ions."
    "We found a higher frequency (100%) of instent restenosis in patients with delayed-type hypersensitivity to metals, particularly to Nickel, than in patients without sensitisation to metals. These findings support the hypothesis that contact allergies to Nickel and Molybdenum trigger instent restenoses to a clinically relevant degree."
    Source: "Nickel and Molybdenum contact allergies in patients with coronary in-stent restenosis"
    Dept of Cardiology, University Hospital Eppendorf, Hamburg, Germany. R. Köster et al. The Lancet, Vol 356, December 2, 2000.
    >> Download STENT ARTICLE (.pdf file, 434Kb)

Next page >>